{"id":50268,"date":"2012-07-27T11:14:45","date_gmt":"2012-07-27T11:14:45","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/coventry-health-care-reports-second-quarter-earnings.php"},"modified":"2012-07-27T11:14:45","modified_gmt":"2012-07-27T11:14:45","slug":"coventry-health-care-reports-second-quarter-earnings","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/health-care\/coventry-health-care-reports-second-quarter-earnings.php","title":{"rendered":"Coventry Health Care Reports Second Quarter Earnings"},"content":{"rendered":"<p><p>    BETHESDA, Md.--(BUSINESS WIRE)--  <\/p>\n<p>    Coventry Health Care, Inc. (CVH)    today reported consolidated operating results for the quarter    ended June 30, 2012. Operating revenues totaled $3.5 billion    for the quarter, with net earnings of $91.7 million or earnings    per diluted share (EPS) of $0.65. These results include a    one-time $7.7 million, or $0.03 EPS, impairment charge    resulting from the write down of intangible assets due to the    non-renewal of the Companys Kansas Medicaid contract effective    January 1, 2013.  <\/p>\n<p>    Our second quarter results reflect strong performance in our    Government Programs businesses including significant    improvement in our Medicaid operations and sequential growth in    our Medicare products, said Allen F. Wise, chairman and chief    executive officer of Coventry. We remain on track for our full    year consolidated 2012 EPS guidance and, although there remains    a great deal of work to be done, I am encouraged by the    financial and operational progress that we have made in our    Kentucky Medicaid business.  <\/p>\n<p>    Second Quarter 2012 Consolidated Highlights  <\/p>\n<p>    Selected Second Quarter 2012 Highlights  <\/p>\n<p>    2012 Full Year Guidance  <\/p>\n<p>    Mr. Allen F. Wise, chairman and chief executive officer of    Coventry, will host a conference call at 8:30 a.m. ET on    Friday, July 27, 2012. To listen to the call, dial toll-free at    (888) 334-3001 or, for international callers, (719) 325-2460.    Callers will be asked to identify themselves and their    affiliations. The conference call will also be webcast from    Coventrys Investor Relations site at     <a href=\"http:\/\/www.coventryhealthcare.com\" rel=\"nofollow\">http:\/\/www.coventryhealthcare.com<\/a>. Coventry asks participants on    both the call and webcast to review and be familiar with its    filings with the Securities and Exchange Commission. A replay    of the call will be available for one week at (888) 203-1112    or, for international callers, (719) 457-0820. The access code    is 4038961.  <\/p>\n<p>    This press release contains forward-looking statements made    pursuant to the safe harbor provisions of the Private    Securities Litigation Reform Act of 1995. Forward-looking    statements are defined as statements that are not historical    facts and include those statements relating to future events or    future financial performance, including the guidance herein.    Actual performance may be significantly impacted by certain    risks and uncertainties including those described in Coventrys    Annual Report on Form 10-K for the year ended December 31,    2011, Coventrys Quarterly Report for the quarter ending March    31, 2012, and Coventrys subsequent filings with the Securities    and Exchange Commission. Among the risk factors that may    materially affect Coventrys business, operations or financial    condition are the ability to accurately estimate and control    future health care costs; the ability to increase premiums to    offset increases in the Companys health care costs; general    economic conditions and disruptions in the financial markets;    changes in legal requirements from recently enacted federal or    state laws or regulations, court decisions, or government    investigations or proceedings; guaranty fund assessments under    state insurance guaranty association law; changes in government    funding and various other risks associated with our    participation in Medicare and Medicaid programs; our ability to    effectively implement and manage our Kentucky Medicaid program,    including the implementation of appropriate risk adjustment    revenue and management of the associated medical cost and the    effect on our MLR; a reduction in the number of members in the    Companys health plans; the Companys ability to acquire    additional managed care businesses and the Companys ability to    successfully integrate acquired businesses into its operations;    an ability to attract new members or to increase or maintain    premium rates; the non-renewal or termination of the Companys    government contracts, unsuccessful bids for business with    government agencies or renewal of government contracts on less    than favorable terms; failure of independent agents and brokers    to continue to market the Companys products to employers; a    failure to obtain cost-effective agreements with a sufficient    number of providers that could result in higher medical costs    and a decrease in membership; negative publicity regarding the    managed health care industry generally or the Company in    particular; a failure to effectively protect, maintain, and    develop our information technology systems; compromises of the    Companys data security; periodic reviews, audits and    investigations under the Companys contracts with federal and    state government agencies; litigation, including litigation    based on new or evolving legal theories; volatility in the    Companys stock price and trading volume; the Companys    indebtedness, which imposes certain restrictions on its    business and operations; an inability to generate sufficient    cash to service the Companys indebtedness; the Companys    ability to receive cash from its regulated subsidiaries; the    Companys certificate of incorporation and bylaws and Delaware    law, which could delay, discourage or prevent a change in    control of the Company that its stockholders may consider    favorable; and an impairment of the Companys intangible    assets. Coventry undertakes no obligation to update or revise    any forward-looking statements.  <\/p>\n<p>    Coventry Health Care (www.coventryhealthcare.com)    is a diversified national managed health care company based in    Bethesda, Maryland, dedicated to delivering high-quality health    care solutions at an affordable price. Coventry provides a full    portfolio of risk and fee-based products including Medicare and    Medicaid programs, group and individual health insurance,    workers compensation solutions, and network rental services.    With a presence in every state in the nation, Coventrys    products currently serve approximately 5 million individuals    helping them receive the greatest possible value for their    health care investment.  <\/p>\n<p>          Selling, general, and administrative        <\/p>\n<\/p>\n<p>Here is the original post:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/coventry-health-care-reports-second-103000623.html;_ylt=A2KJjbwZeBJQI1kAX3D_wgt.\" title=\"Coventry Health Care Reports Second Quarter Earnings\">Coventry Health Care Reports Second Quarter Earnings<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> BETHESDA, Md.--(BUSINESS WIRE)-- Coventry Health Care, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/health-care\/coventry-health-care-reports-second-quarter-earnings.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[6],"tags":[],"class_list":["post-50268","post","type-post","status-publish","format-standard","hentry","category-health-care"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/50268"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=50268"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/50268\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=50268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=50268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=50268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}